title: Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.
abstract: BACKGROUND
  Acute myeloid leukemia (AML) cases with t(8;21) or inv(16) have a favorable outcome, but the associated prognoses are heterogeneous and complicated by additional molecular aberrations.
  
  
  METHODS
  Between January 2000 to December 2010, 67 patients were diagnosed with t(8;21) or inv(16) AML. We collected cytogenetic variables and analyzed treatment outcomes.
  
  
  RESULTS
  Among 67 patients, 51 (7.8%) had t(8;21) AML and 16 (2.4%) had inv(16) AML. Thrombocytopenia, and a high percentage of blasts in the peripheral blood and bone marrow were associated with poor overall survival. Twenty-five (49.0%) patients with t(8;21) had an additional chromosomal abnormality, while only six (37.5%) patients with inv(16) AML had a secondary chromosomal abnormality. The most common chromosomal abnormalities were deletion of the Y or X sex chromosomes.
  
  
  CONCLUSIONS
  Deletion of the Y chromosome may be a favorable prognostic factor in patients with core binding factor-positive AML.
authors: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea. jh21.jang@samsung.com, chulwon1.jung@samsung.com.
authors: Hyun Ae
authors: HA
authors: Jung
authors: Chi Hoon
authors: CH
authors: Maeng
authors: Silvia
authors: S
authors: Park
authors: Seok Jin
authors: SJ
authors: Kim
authors: Kihyun
authors: K
authors: Kim
authors: Jun Ho
authors: JH
authors: Jang
authors: Chul Won
authors: CW
authors: Jung
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D050660:Core Binding Factors / Q000096:biosynthesis* / Q000235:genetics; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D014178:Translocation, Genetic; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D050660:Core Binding Factors; D003561:Cytarabine; D015255:Idarubicin
keywords: Core-binding factor-positive AML; prognostic factor